Vivos wins FDA clearance to launch Mayo Clinic feasibility study for RadioGel thyroid cancer therapy
RDGL•Veterinary network and facility updates
The Veterinary IsoPet network expanded to 17 certified U.S. clinics, treating more than 200 small animals and horses.
Validation work at the Richland, Washington facility neared completion; shipments for veterinary use are targeted by quarter-end.
FDA clearance for Mayo Clinic feasibility study
Vivos received FDA clearance on July 22, 2026 for a Feasibility IDE to start a first-in-human study at Mayo Clinic in Jacksonville.
Initial enrollment is set at 5 patients with non-resectable papillary thyroid carcinoma to assess safety and feasibility.
The FDA shortened the required safety follow-up to 24 months from 5 years, cutting the period by about 60%.
